CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.
about
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugsSelective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels.Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitratesNeuroinflammation and related neuropathologies in APPSL mice: further value of this in vivo model of Alzheimer's disease.Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease.Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice.Advances in recent patent and clinical trial drug development for Alzheimer's disease.Alzheimer's disease and the amyloid cascade hypothesis: a critical review.Therapeutic effect of CHF5074, a new γ-secretase modulator, in a mouse model of scrapie.Chemical Biology, Molecular Mechanism and Clinical Perspective of γ-Secretase Modulators in Alzheimer's DiseaseAmyloid Hypothesis: Is There a Role for Antiamyloid Treatment in Late-Life Depression?Inhibition of serine palmitoyltransferase reduces Aβ and tau hyperphosphorylation in a murine model: a safe therapeutic strategy for Alzheimer's diseaseAn update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease.Pharmacological targeting of the β-amyloid precursor protein intracellular domain.Evodiamine improves congnitive abilities in SAMP8 and APP(swe)/PS1(ΔE9) transgenic mouse models of Alzheimer's disease.γ-Secretase inhibitors and modulators for Alzheimer's disease.Consequences of inhibiting amyloid precursor protein processing enzymes on synaptic function and plasticity.Review: experimental manipulations of microglia in mouse models of Alzheimer's pathology: activation reduces amyloid but hastens tau pathology.Interpreting Alzheimer's disease clinical trials in light of the effects on amyloid-β.Discovery of BIIB042, a Potent, Selective, and Orally Bioavailable γ-Secretase Modulator.Neuroprotective and Anti-Apoptotic Effects of CSP-1103 in Primary Cortical Neurons Exposed to Oxygen and Glucose DeprivationCHF5074 restores visual memory ability and pre-synaptic cortical acetylcholine release in pre-plaque Tg2576 mice.Alzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy.CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects.The γ-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer's disease.CHF5074 (CSP-1103) stabilizes human transthyretin in mice humanized at the transthyretin and retinol-binding protein loci.Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to γ-secretase modulators regardless of their potency and structure.
P2860
Q26866006-B051C5C8-38DC-4040-A270-231E8DAD7B7FQ33496258-D1E19468-2A6B-4FED-8E83-A64ED14EB077Q33846317-D5ADEECD-37DA-4AD3-930A-7E3F3FD471E1Q33939172-8B676900-7555-42E8-A341-9C791F415C54Q34543713-FE89B16C-2F27-45C9-A56D-FF121CBBAAA4Q34656871-BEC00A5A-CD22-4D2F-92DA-B529F483406BQ35738142-1D244D4C-9F0E-42B6-AE8F-5C57D8C4F97AQ35855587-17F3E04B-2F84-4E60-B9A1-0FC762E46D93Q35918940-465740BF-100F-4DCA-B0A4-88F3F5F14A45Q36081889-5B83A368-60AC-4D3C-81BD-4D36E2A4B586Q36711795-7B110723-50D6-40E4-838E-53597A4EA114Q36836935-DC3035D9-0AC7-466A-B21F-10849F261F9BQ37546119-D5FF06EC-9843-4BF9-90A0-BBFABAA03431Q37693126-3E7D0586-8BFE-4760-BE4B-5BCFF207996FQ37728870-0FEACC25-7A03-469A-89C8-268008255AF0Q37961792-F0A6BC70-05A8-4BB9-BA91-FF9B8E173C72Q38026045-107D3CBF-D260-4474-82A7-D09811E13B2EQ38061480-B636E3D1-4D0B-420D-9B3D-3EE3DC9C2A8FQ38230384-708E8ECC-124C-45A9-89D4-71A18DF96F6CQ39511082-9B427A18-2BF6-4155-93B8-A4238166BAAAQ41895193-9C22C3C9-8CB8-492C-9D36-781ED301805EQ45912487-22EB5BF6-679E-44E1-B1D5-AD7EC9AC83F4Q47222390-D46E1FA1-8DA8-4686-8A91-21EA3ED2865EQ47924309-EE5B8FA5-595A-48EE-985E-CC90DEE3D446Q51026158-AC3E1710-5AF1-49A9-8D83-3DABCA401D14Q51654182-DD164DD6-0B0E-45CC-B3B7-067DE1CB01C2Q51770733-B903AAD4-A709-40AE-BFC7-0A6A469111A4
P2860
CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CHF5074, a novel gamma-secreta ...... model of Alzheimer's disease.
@en
CHF5074, a novel gamma-secreta ...... model of Alzheimer's disease.
@nl
type
label
CHF5074, a novel gamma-secreta ...... model of Alzheimer's disease.
@en
CHF5074, a novel gamma-secreta ...... model of Alzheimer's disease.
@nl
prefLabel
CHF5074, a novel gamma-secreta ...... model of Alzheimer's disease.
@en
CHF5074, a novel gamma-secreta ...... model of Alzheimer's disease.
@nl
P2093
P2860
P1476
CHF5074, a novel gamma-secreta ...... e model of Alzheimer's disease
@en
P2093
A Lanzillotta
B Hutter-Paier
F Facchinetti
G Villetti
M Windisch
V Cenacchi
P2860
P304
P356
10.1111/J.1476-5381.2008.00097.X
P407
P577
2009-03-01T00:00:00Z